Characteristic (n = 164) | Number (%) |
---|---|
Median age at presentation, range (n = 164) | 50, 30–93 years |
Referral (n = 164)a | |
 Yes | 74 (45%) |
 No | 90 (55%) |
Mwanza City Residence (n = 164)b | |
 Yes | 34 (21%) |
 No | 130 (79%) |
Insurance (n = 164) | |
 Yes | 50 (30%) |
 No | 114 (70%) |
Menopause Status (n = 164) | |
 Pre-menopausal | 61 (37%) |
 Post-menopausal | 70 (43%) |
 Not reported | 33 (20%) |
Breast Symptoms at Presentation (n = 164) | |
 Yes | 164 (100%) |
 No | 0 (0%) |
Clinically Positive Nodes Reported (n = 164) | |
 Suspected | 23 (14%) |
 Not suspectedc | 141 (86%) |
Suspected Distant Metastases (n = 164) | |
 Yes | 26 (16%) |
 No | 138 (84%) |
Surgery (n = 164) | |
 Yes | 135 (82%) |
 No | 29 (18%) |
Surgical Procedure (n = 135) | |
 Excision/Lumpectomy | 25 (19%) |
 Unilateral Mastectomy | 88 (65%) |
 Bilateral Mastectomy | 4 (3%) |
 Other/Unknown | 18 (13%) |
Axillary evaluation (n = 135) | |
 Yes | 75 (56%) |
 No | 60 (44%) |
Chemotherapy prescribed (n = 164) | |
 Yes | 103 (63%) |
 No | 61 (37%) |
Chemotherapy basis (n = 103) | |
 Proven histopathology | 57 (56%) |
 Symptoms | 2 (2%) |
 Other (imaging, FNAC, clinical suspicion) | 43 (42%) |
Chemotherapy Received (n = 103) | |
 Yes | 81 (79%) |
 No | 22 (21%) |
Hormone therapy (n = 164) | |
 Yes | 63 (38%) |
 No | 101 (62%) |
Basis for hormone therapy (n = 63) | |
 Proven receptor status | 9 (15%) |
 Clinical suspicion | 54 (86%) |
Radiation therapy (n = 164) | |
 Yes | 5 (3%) |
 No | 197 (97%) |
Adjuvant therapyd | |
 Yes | 100 (61%) |
 Chemotherapy | 81 (81%) |
 No | 64 (39%) |